ShanXi C&Y Pharmaceutical Group Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 402.85 million compared to CNY 455.26 million a year ago. Revenue was CNY 404.96 million compared to CNY 457.83 million a year ago.

Net loss was CNY 22.83 million compared to CNY 4.12 million a year ago. Basic loss per share from continuing operations was CNY 0.0982 compared to CNY 0.0181 a year ago. Diluted loss per share from continuing operations was CNY 0.0982 compared to CNY 0.0181 a year ago.